HD 101 CME Series

COURSE DESCRIPTION;

TO RECEIVE ACCME CREDITS FOR THESE ACTIVITIES, you must complete the HDSA registration, the self-assessment, view the recorded lecture and complete the post assessment and evaluation. Each successfully completed activity provides one CME credit.

PURPOSE STATEMENT:

These online CME activities are designed to offer expert knowledge about Huntington’s disease (HD) to primary care providers and family practitioners who care for people with HD at the local level. They also target neurologists and psychiatrists who are not familiar with HD. The activity will cover the natural history of the disease, genetics of HD, the psychiatric, neuropsychological and motor symptoms of the disease with treatment options as well as covering Juvenile Onset HD, assembling a team to provide care, information on research and clinical trials for people with HD and documenting disability for a person with HD.

TARGET AUDIENCE:

The target audience for this self-study CME activity is primary care providers, family practitioners, general neurologists and psychiatrists.

 

ACCREDITATION STATEMENT;

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Alabama School of Medicine and the Huntington’s Disease Society of America (HDSA). The University of Alabama School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.

 

CREDIT DESIGNATION: The University of Alabama School of Medicine designates each activity for a maximum of 1.00 hour(s) AMA PRA™ Category 1 Credit. Each physician/learner should claim only those credits that he/she actually spent in the activity.

 

OFF LABEL DISCLOSURE:
These educational activities include discussion of the off-label use of some medications.

 

TECHNICAL REQUIREMENTS;
The following hardware/software specifications must be met or exceeded to complete these activities:

  • Web browser and Internet connection
  • Free flash plug-in version 8 or higher
  • Computer equipped with audio output (speakers or headphones)
  • Printer
  • Pop-up windows enabled for viewing support materials

 

INSTRUCTIONS TO PARTICIPANTS:

  1. There is no fee charged for participation in this CME activity.
  2. Read the target audience, purpose statement, and author disclosures on this screen.
  3. Study the educational activity as presented on this web site.
  4. Read, complete and submit answers to the Review Questions and complete the Evaluation Form. These documents are available on the last screen of this CME activity.
  5. Print the CME certificate.

 

ADDITIONAL RESOURCES:

For Huntington’s disease: Huntington’s Disease Society of America (HDSA): www.hdsa.org

For Clinical Trials: www.hdsa.org; www.clinicaltrials.gov; HDTrialfinder.org

 

FACULTY INFORMATION AND DISCLOSURE:
The University of Alabama School of Medicine requires that faculty participating in CME activity disclose any relationship that might pose a potential, apparent, or real conflict of interest. The authors of this CME activity indicated that there were the following relationships to disclose.

 

Kevin Biglan, MD: Disclosures will appear on presentation
Thomas Bird, MD: Licensing fees and Speaker’s bureau for Athena Diagnostics
Samuel Frank, MD: Research and consulting fees from Lundbeck, Inc.
Martha Nance, MD: Research support grant from Medivation and NeuroSearch; Spouse on Speaker’s Bureau for Roche and Genentech.
Jane Paulsen, PhD: Support from National Institutes (NIH), National Institute for Neurological Disorders and Stroke (NINDS – NS40068 and NS054893), the Huntington’s Disease Society of America and CHDI Foundation, Inc.
Adam Rosenblatt, MD: Disclosures will appear on presentation
Vicki Wheelock, MD: Honorarium for A Physician’s Guide to the Management of Huntington’s Disease (Third Edition), educational grant from Lundbeck, Inc.

 

DISCLAIMER:

The material presented here does not necessarily reflect the views of the Huntington’s disease Society of America (HDSAS) or the University of Alabama School of Medicine. These materials may discuss therapeutic products that have not been approved by the U.S. Food and Drug Administration and off-label uses of approved products. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

 

LEARNING OBJECTIVES: After completing this self-directed study, the participant should be able to:

  • Understand the diagnostic criteria and current neurologic management of Huntington’s disease (ABMS/ACGME Competencies: Medical Knowledge, Patient Care).
  • Understand the psychiatric manifestations of HD and their treatment (ABMS/ACGME Competencies: Medical Knowledge, Patient Care).
  • Gain awareness of cognitive features of HD and the role of neuropsychological assessment (ABMS/ACGME Competencies: Medical Knowledge, Patient Care).
  • Understand the benefits, limitations and ethical issues of genetic testing in HD (ABMS/ACGME Competencies: Medical Knowledge, Patient Care).
  • Appreciate the role of the multidisciplinary team in the management of HD including long-term care (ABMS/ACGME Competencies: Medical Knowledge, Patient Care).
  • Acquire knowledge and understanding of prevalence and diagnostic procedures utilized for the juvenile form of HD (ABMS/ACGME Competencies: Medical Knowledge, Patient Care).
  • Expand understanding of unique issues pertaining to quality of life in HD (ABMS/ACGME Competency: Patient Care).
  • Increase knowledge of resources to connect HD patients and families with clinical research opportunities in their geographic areas (ABMS/ACGME Competency: Patient Care).

 

Module 1: NATURAL HISTORY OF HD AND INTRODUCTION TO SERIES

Explores the stages and progression of Huntington’s disease
Presented by Sam Frank, MD
Run time: 48 minutes

 

Module 2: GENETIC FACTORS IN HD

Addresses heredity, CAG repeat and what that means as well as genetic testing for HD
Presented by Tom Bird, MD
Run time: 34 minutes

 

Module 3: SPECIAL ISSUES- THE PRODROME OF HD

Describers the early signs of HD prior to motor diagnosis
Presented by Jane Paulsen, PhD
Run time: 57 minutes

 

Module 4: COGNITIVE FEATURES OF HD

How cognition is impacted by Huntington’s disease
Presented by Jane Paulsen, PhD
Run time: 46 minutes

 

Module 5: PSYCHIATRIC SYNDROMES IN HUNTINGTON’S DISEASE – ASSESSMENT AND MANAGEMENT

Describes the psychiatric syndromes associated with HD and treatment options
Presented by Adam Rosenblatt, MD
Run time: 46 minutes

 

Module 6: MOTOR DYSFUNCTION AND NEUROLOGICAL CARE

Addresses the movement disorders associated with HD and treatment options
Presented by Vicki Wheelock, MD
Run time: 37 minutes

 

Module 7: JUVENILE HD

Describes diagnosis, treatment and care for children affected by the juvenile version of HD
Presented by Martha Nance, MD
Run time: 21 minutes

 

Module 8: TEAM BASED CARE FOR HD – FROM THE BEGINNING TO THE END

Discusses the benefits of a team based care approach to improving the quality of life and overall care of the person with HD
Presented by Martha Nance, MD
Run time: 35 minutes

 

Module 9: AN OVERVIEW OF EXPERIMENTAL THERAPEUTICS IN HUNTINGTON’S DISEASE

Describes the clinical trial process and currently recruiting trials for HD
Presented by Kevin Biglan, MD
Run time: 40 minutes

 

Module 10: DISABILITY, ADVOCACY AND CONCLUSIONS

Explains how physicians can effectively document disability in a person with HD as well as series conclusions
Presented by Sam Frank, MD
Run time: 25 minutes

Share Tweet

Share a link